Skip to main contentSkip to navigationSkip to navigation
CVS, Walmart and Walgreens have said they will appeal against award by court in Cleveland, Ohio.
CVS, Walmart and Walgreens have said they will appeal against award by court in Cleveland, Ohio. Photograph: AP
CVS, Walmart and Walgreens have said they will appeal against award by court in Cleveland, Ohio. Photograph: AP

US pharmacies ordered to pay $650.6m for role in opioids crisis

This article is more than 1 year old

CVS, Walgreens and Walmart must pay damages to two Ohio counties for oversupplying pills that ended up on black market

The US pharmacy chains CVS, Walmart and Walgreens must pay a combined $650.6m to two Ohio counties to address the damage done by the opioid epidemic, a federal judge ruled on Wednesday.

The order by US judge Dan Polster in Cleveland comes after a jury last November concluded that the firms helped create a public nuisance in Lake and Trumbull counties by oversupplying addictive pain pills, many of which found their way to the black market. The companies have said they would appeal that verdict.

Polster held a separate non-jury trial earlier this year to decide how much the companies had to pay.

“We are disappointed with this outcome,” a Walgreens spokesman, Fraser Engleman, said in a statement. “The facts and the law did not support the jury verdict last fall, and they do not support the court’s decision now.”

CVS and Walmart did not immediately respond to requests for comment.

Polster said the sum must be paid over 15 years, with the amount for the first two years, or $86.7m, to be paid into a fund immediately. The judge also ordered the companies to implement new procedures to combat illegal diversion of opioid drugs.

The US opioid epidemic has caused more than 500,000 overdose deaths over two decades, according to government data. More than 3,300 opioid lawsuits have been filed nationally against drugmakers, distributors and pharmacy chains.

The litigation has resulted in several nationwide settlements, including a $26bn deal with Johnson & Johnson and the three leading distributors, a $2.37bn settlement with AbbVie Inc and a $4.25bn settlement with Teva Pharmaceutical Industries Ltd.

Pharmacies have yet to reach a nationwide settlement.

Most viewed

Most viewed